A Val 677 activating mutation of the thyrotropin receptor in a Hurthle cell thyroid carcinoma associated with thyrotoxicosis

被引:49
作者
Russo, D
Wong, MG
Costante, G
Chiefari, E
Treseler, PA
Arturi, F
Filetti, S
Clark, OH [1 ]
机构
[1] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA
[3] Univ Catanzaro, Fac Farm, Cattedra Farmacol, Catanzaro, Italy
关键词
D O I
10.1089/thy.1999.9.13
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thyroid nodules presenting as hot at I-131-scintigraphy are usually benign follicular adenomas. We report a 42-year-old female patient with an autonomously functioning Hurthle cell thyroid carcinoma causing thyrotoxicosis. Genetic analysis of her thyroid tumoral DNA revealed a heterozygotic activating mutation of the thyrotropin receptor (TSHR) gene that was located downstream to all of the other genetic alterations currently identified, and is due to a base substitution at codon 677 (normal cytosine replaced by guanine, CTG for GTG causing leucine substitution by valine in the seventh transmembrane domain of the receptor). This mutation was detected in the tumor, but not in the leucocytes from the same patient. The Val 677-TSHR mutant showed constitutive activity, in terms of cyclic adenosine monophosphate (cAMP) production, when permanently transfected in Chinese hamster ovary (CHO) cells. Gsp and ras oncogenes and the p53 tumor suppressor gene were not present in the Hurthle cell cancer. The TSHR mutation in this Hurthle cell carcinoma may be responsible for maintaining differentiated thyroid function and hyperthyroidism.
引用
收藏
页码:13 / 17
页数:5
相关论文
共 32 条
[1]   MANAGEMENT CONSIDERATIONS IN HURTHLE CELL-CARCINOMA [J].
AZADIAN, A ;
ROSEN, IB ;
WALFISH, PG ;
ASA, SL .
SURGERY, 1995, 118 (04) :711-715
[2]   HIGH-EFFICIENCY TRANSFORMATION OF MAMMALIAN-CELLS BY PLASMID DNA [J].
CHEN, C ;
OKAYAMA, H .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (08) :2745-2752
[3]  
CHEN H, 1997, TXB ENDOCRINE SURG, P103
[4]   THYROTROPIN RECEPTOR-ADENYLATE CYCLASE SYSTEM IN HURTHLE CELL NEOPLASMS [J].
CLARK, OH ;
GEREND, PL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 61 (04) :773-778
[5]   MORBIDITY AND MORTALITY IN FOLLICULAR THYROID-CANCER [J].
DEGROOT, LJ ;
KAPLAN, EL ;
SHUKLA, NS ;
SALTI, G ;
STRAUS, FH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (10) :2946-2953
[6]   Constitutive activation of the G(s)alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas [J].
Derwahl, M ;
Hamacher, C ;
Russo, D ;
Broecker, M ;
Manole, D ;
Schatz, H ;
Kopp, P ;
Filetti, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (05) :1898-1904
[8]   MOLECULAR-BASIS OF THYROID-CANCER [J].
FARID, NR ;
SHI, YF ;
ZOU, MJ .
ENDOCRINE REVIEWS, 1994, 15 (02) :202-232
[9]   THE ROLE OF THYROID-STIMULATING ANTIBODIES OF GRAVES-DISEASE IN DIFFERENTIATED THYROID-CANCER [J].
FILETTI, S ;
BELFIORE, A ;
AMIR, SM ;
DANIELS, GH ;
IPPOLITO, O ;
VIGNERI, R ;
INGBAR, SH .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (12) :753-759
[10]   THE BIOLOGICAL-ACTIVITY OF BOVINE AND HUMAN THYROTROPIN IS DIFFERENTLY AFFECTED BY TRYPSIN TREATMENT OF HUMAN THYROID-CELLS - THYROID-STIMULATING ANTIBODY IS RELATED TO HUMAN THYROTROPIN [J].
FOTI, D ;
RUSSO, D ;
COSTANTE, G ;
FILETTI, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (04) :710-716